Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Selina Moy"'
Autor:
Srinivasu Poondru, Vitalii Ghicavii, Reza Khosravan, Pooja Manchandani, Nakyo Heo, Selina Moy, Tomasz Wojtkowski, Melanie Patton, Gabriel P. Haas
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 5, Pp 1131-1142 (2022)
Abstract Drug‐drug interaction (DDI) is an important consideration for clinical decision making in prostate cancer treatment. The objective of this study was to evaluate the effect of enzalutamide, an oral androgen receptor inhibitor, on the pharma
Externí odkaz:
https://doaj.org/article/cc204e83d67f46e2a224c3bb586df58b
Autor:
Vishala Chindalore, Ying Cao, Tong Zhu, Wenhui Zhang, Bola Akinlade, Taiji Sawamoto, Udaya Valluri, Selina Moy
Publikováno v:
Clinical Drug Investigation
Background Methotrexate is frequently used to treat rheumatoid arthritis. Peficitinib (ASP015K; Smyraf®), an oral Janus kinase inhibitor indicated for the treatment of rheumatoid arthritis, may be coadministered with methotrexate. Objective The obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a59dda548dbfa3349d37a95216bab01
http://europepmc.org/articles/PMC7452880
http://europepmc.org/articles/PMC7452880
Autor:
Chaofeng Liu, Melanie Patton, Mark R. Litzow, Dale R. Shepard, Erkut Bahceci, Selina Moy, Catherine C. Smith, Angela Joubert James, Zheng Lu, Alexander E. Perl, Kinya Souda, Takeshi Kadokura, Jessica K. Altman, Mark J. Levis
Publikováno v:
Clinical Pharmacokinetics
Clinical pharmacokinetics, vol 59, iss 10
Clinical pharmacokinetics, vol 59, iss 10
Background and Objective Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4afe889b7393ad7f418925126988fb4
http://europepmc.org/articles/PMC7550323
http://europepmc.org/articles/PMC7550323
Autor:
Amit Desai, Stephen Stanhope, Nakyo Heo, Melanie Helmick, Selina Moy, Nancy Martin, Ronald Goldwater
Publikováno v:
Antimicrobial Agents and Chemotherapy
For critically ill patients with invasive fungal infections, a nasogastric (NG) tube can be an alternative route for administration of isavuconazonium sulfate (ISAVUSULF). This was a randomized, open-label, 2-period, 2-sequence single-dose crossover
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb25b4964b851b823a432d3f6eb88681
https://pubmed.ncbi.nlm.nih.gov/34181478
https://pubmed.ncbi.nlm.nih.gov/34181478
Autor:
Mark J. Levis, Catherine C. Smith, Angela Joubert James, Melanie Patton, Dale R. Shepard, Mark R. Litzow, Jessica K. Altman, Kinya Souda, Chaofeng Liu, Takeshi Kadokura, Selina Moy, Erkut Bahceci, Alexander E. Perl, Zheng Lu
Publikováno v:
Clinical Pharmacokinetics
Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the clinical pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ee8ac6c0f5235998323d8d202fa14a
https://doi.org/10.1007/s40262-021-01060-8
https://doi.org/10.1007/s40262-021-01060-8
Autor:
Yuki Nomura, Kentaro Kuroishi, Selina Moy, Atsunori Kaibara, Junko Toyoshima, Toshifumi Hatta, Taiji Sawamoto, Masataka Katashima, Hiromi Iitsuka
Publikováno v:
Drug Metabolism and Pharmacokinetics. 31:411-416
Mirabegron, the first selective β3-adrenoceptor agonist for the treatment of overactive bladder (OAB), inhibits cytochrome P450 isozyme CYP2D6. This study was performed in Japanese healthy postmenopausal female volunteers to assess any pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f6ea7962499632dfdd984303e6db006
https://doi.org/10.1016/j.dmpk.2016.08.002
https://doi.org/10.1016/j.dmpk.2016.08.002
Autor:
Amit Desai, Ronald Goldwater, Nakyo Heo, Stephen Stanhope, Selina Moy, Nancy Martin, Melanie Helmick
Publikováno v:
Open Forum Infectious Diseases
Background Nasogastric (NG) tube feeding is most common in the intensive care unit and is also used for cancer patients who are unable to eat (e.g. patients with mucositis) or do not want to eat due to severe nausea1. For such critically ill patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a09533c1f0df6736fadbc8ea62cdd80
http://europepmc.org/articles/PMC7777323
http://europepmc.org/articles/PMC7777323
Autor:
Virginie Kerbusch, Walter Krauwinkel, Selina Moy, Alan Marion, Donna Kowalski, Michael Roy, James Keirns, Taiji Sawamoto, Jennifer Lee, Marcel van Gelderen, John Meijer, Shin Takusagawa
Publikováno v:
Clinical Drug Investigation. 33:429-440
Mirabegron is a β3-adrenoceptor agonist for the treatment of overactive bladder. There has been little information published or presented about the involvement of cytochrome P450 (CYP) isoenzymes 3A and 2D6 in the metabolism of mirabegron in humans;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e77f60f4009cebac2dbca806031d271
https://doi.org/10.1007/s40261-013-0084-y
https://doi.org/10.1007/s40261-013-0084-y
Autor:
Marcel van Gelderen, Taiji Sawamoto, Jennifer Lee, Virginie Kerbusch, Nicole Grunenberg, Wenhui Zhang, Donna Kowalski, Selina Moy, James Keirns
Publikováno v:
Clinical Therapeutics. 35:333-341
Background Mirabegron is a β3-adrenoceptor agonist used for the treatment of overactive bladder. Mirabegron is formulated as an extended-release tablet using oral controlled-absorption system (OCAS) technology. Objective This study was designed to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::862d9a65e57be577ff27fe8b26fd46bd
https://doi.org/10.1016/j.clinthera.2013.02.014
https://doi.org/10.1016/j.clinthera.2013.02.014
Autor:
Selina Moy, M P Schaddelee, Marek Malik, Salim Mujais, Jennifer Lee, Donna Kowalski, P de Koning, James Keirns, Atsunori Kaibara, Mark Yen, Ronald Goldwater, E M van Gelderen
Publikováno v:
Clinical Pharmacology & Therapeutics. 92:696-706
Potential effects of the selective β(3)-adrenoceptor agonist mirabegron on cardiac repolarization were studied in healthy subjects. The four-arm, parallel, two-way crossover study was double-blind and placebo- and active (moxifloxacin)-controlled. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5910ab8061ce852bd711805cd4dc83a
https://doi.org/10.1038/clpt.2012.181
https://doi.org/10.1038/clpt.2012.181